新穎生醫

Latest News

News

  • News

2026/11/04 Press

DNlite Steps Into Regional Hospitals

Commercial Milestone Precision Diagnostics · Stock Code: 6810

DNlite Steps Into Regional Hospitals:
Bio Preventive Medicine Secures Self-Pay Billing Approval

Official self-pay billing code approval unlocks routine clinical adoption at regional hospitals and medical centers across Taiwan—building on over 60% partnership growth in primary care.

CLINICAL ADOPTION · DNlite™
ZHUBEI, TAIWAN — Bio Preventive Medicine Corp. (BPM; Stock Code: 6810) announced that DNlite (遠腎佳), its independently developed precision kidney function test, has officially received self-pay billing approval (self-pay code) for medical institutions at the regional hospital level and above in Taiwan. This milestone establishes a standardized clinical billing foundation for DNlite and propels its expansion from primary care clinics and health screening centers into mid-sized and large medical institutions.
Regulatory & Billing Access
Regional+
Hospital-Tier Self-Pay Code
Approved for medical institutions at regional hospital level and above in Taiwan
Primary Care Momentum
> 60%
Partnership Network Growth
Increase in signed partner institutions as of Q3 2026 vs. year-end 2025
Commercial Strategy
Dual-Track
Clinics × Major Hospitals
Connecting grassroots preventive screening with specialist outpatient care

Dual-Engine Expansion: From Primary Care Screening to Major Hospital Systems

Hospital Systems · Billing Readiness

Expanding Into Mid-Sized and Large Medical Institutions

Under Taiwan’s healthcare regulatory framework, securing an approved institutional self-pay billing code is an essential prerequisite for integrating innovative precision diagnostics into routine hospital workflows.

With self-pay billing approval now in place for regional hospitals and above, DNlite is well positioned to accelerate hospital onboarding and enter core clinical settings—including nephrology and endocrinology outpatient departments as well as hospital-based executive health centers.

  • Establishes compliant self-pay billing for regional hospitals & above
  • Supports adoption across specialist clinics and advanced health checkups
Primary Care · Accelerating Adoption

Signed Institutional Partnerships Surpass 60% Growth

Alongside its entry into larger hospital tiers, BPM continues to see strong commercial traction across primary care clinics and preventive health screening centers throughout Taiwan.

As of Q3 2026, the number of medical and health screening institutions with signed DNlite partnerships grew by more than 60% compared with the end of 2025, reflecting growing clinical recognition of early, non-invasive kidney risk assessment.

  • >60% growth in signed partner institutions by Q3 2026 vs. end of 2025
  • Strengthens community-level early detection and proactive risk management

Building a Seamless Continuum of Precision Kidney Care

By pairing rapid primary care network expansion with formal billing access in regional hospitals and medical centers, DNlite bridges early community screening with specialist clinical management—empowering physicians and patients to intervene earlier against kidney function decline.

Relevant News & Media Sources

Click below to view full financial media coverage (links open in a new tab; articles in Traditional Chinese):

Economic Daily News (UDN)
DNlite Secures Key Self-Pay Code as BPM Steps Into Major Hospitals
Yahoo! Finance Taiwan
BPM’s DNlite Receives Self-Pay Billing Code, Expanding Into Mid-to-Large Hospitals
Liberty Times Finance (LTN)
DNlite Obtains Regional Hospital Self-Pay Approval, Broadening BPM’s Clinical Footprint

About Bio Preventive Medicine Corp. (BPM) & DNlite

Bio Preventive Medicine Corp. (BPM; Stock Code: 6810) is a precision diagnostics innovator specializing in the discovery of post-translationally modified (PTM) protein biomarkers and the development of high-value in vitro diagnostic (IVD) assays. Its flagship product, DNlite (遠腎佳 / uPTM-FetA), is a non-invasive urinary precision kidney function test designed to detect early renal microenvironment injury and stratify kidney progression risk, enabling clinicians and individuals to act within the optimal therapeutic window.

Contact: Tel: +886 3 560 1816 ｜ Website: www.bpmbiotech.com ｜ Email: dnlite@bpmbiotech.com

Back to List

Related News

BPM’s Cross-Ethnic DKD Clinical Study Published in Top-Tier American Journal of Nephrology

Paving the Way for US Market Entry

2023/10/13

Press

BPM Sets a New Record: DNlite-IVD103 Secures Dual SFDA Approvals in Saudi Arabia

BPM Sets a New Record: DNlite-IVD103 Secures Dual SFDA Approvals in Saudi Arabia

2023/12/08

Press

BPM’s DNlite-IVD103 Granted Regulatory Approval in Thailand, Marking Its Third Global Market Entry

BPM’s DNlite-IVD103 Granted Regulatory Approval in Thailand, Marking Its Third Global Market Entry

2023/10/16

Press